-
Mashup Score: 1054Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 2 month(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3Biotech launches with $82 million for Parkinson’s cell therapy - 3 month(s) ago
Kenai Therapeutics plans to move into a clinical trial within the year for its lead drug candidate for people with Parkinson’s.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 9Parkinsonism Case Tied to Welding, Improved With Chelation - 5 month(s) ago
How one team pinpointed manganese toxicity and diminished a patient’s motor symptoms
Source: www.medpagetoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5Palliative Care Training for Neurologists Boosts QOL in PD - 6 month(s) ago
Training community neurologists in palliative care and providing related specialist services via telemedicine to patients with Parkinson’s disease improves patients’ quality of life.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5Palliative Care Training for Neurologists Boosts QOL in PD - 6 month(s) ago
Training community neurologists in palliative care and providing related specialist services via telemedicine to patients with Parkinson’s disease improves patients’ quality of life.
Source: www.medscape.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 3
Using data to train AI to look for biomarkers could clue researchers into much more about Parkinson’s disease, like how it presents and evolves over time.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 23 Key Updates in Parkinson’s Disease - 6 month(s) ago
Nearly one million people in the US live with Parkinson’s disease. The condition is the second-most common neurodegenerative disorder after Alzheimer’s disease, and prevalence is expected to rise by at least 20 percent by 2030. Three recent developments are encouraging for the future of Parkinson’s patients: A study that identifies mitochondrial DNA damage as a […]
Source: www.psychiatrist.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 23 Key Updates in Parkinson’s Disease - 6 month(s) ago
Nearly one million people in the US live with Parkinson’s disease. The condition is the second-most common neurodegenerative disorder after Alzheimer’s disease, and prevalence is expected to rise by at least 20 percent by 2030. Three recent developments are encouraging for the future of Parkinson’s patients: A study that identifies mitochondrial DNA damage as a […]
Source: www.psychiatrist.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 13 Key Updates in Parkinson’s Disease - 6 month(s) ago
Nearly one million people in the US live with Parkinson’s disease. The condition is the second-most common neurodegenerative disorder after Alzheimer’s disease, and prevalence is expected to rise by at least 20 percent by 2030. Three recent developments are encouraging for the future of Parkinson’s patients: A study that identifies mitochondrial DNA damage as a […]
Source: www.psychiatrist.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 11Collections | npj Digital Medicine - 7 month(s) ago
Collections
Source: www.nature.comCategories: General Medicine News, Future of MedicineTweet
Some exciting new GLP-1 drug randomized trial evidence for *potential* disease-modifying impact on #Parkinsons disease (there are none). No progression of motor disability in the Rx group for 12 months. https://t.co/FCNjfIiZT5 https://t.co/NPusWtLXRO